Nicola Blundo has held various roles throughout their work experience. Since 2008, they have been working as the CFO at IBI Lorenzini, a multinational pharmaceutical company. In this role, they are responsible for overseeing all finance, information technology, and innovation functions and supervises a team of 20 people. Nicola'sresponsibilities include financial budgeting and forecasting, preparation of financial reports, and managing costs.
From 2009 to 2016, Nicola also served as a board member at Polo Lionello Bonfanti Spa, a company that participates in the Economy of Communion project.
Prior to their role at IBI Lorenzini, they worked at Wyeth Lederle Spa as a Senior Tax Manager & Controller from 1996 to 2008.
Nicola Blundo completed a degree in Business & Economy with a specialization in Financials & Economics from Sapienza Università di Roma, from 1985 to 1990. In 1992, Nicola obtained a certification as a Certified Chartered Accountant from Università degli Studi di Roma 'La Sapienza'. In 1994, Nicola also obtained a certification as a Certified Public Accountant from Ministero dell'Economia e delle Finanze. In 2007, Nicola pursued further education and completed a master's degree in Business Administration and Management from Alma Business School Bologna.
IBI - Istituto Biochimico Italiano Giovanni Lorenzini S.p.a.
IBI (Istituto Biochimico Italiano G. Lorenzini Spa) is a leading international biopharmaceutical company that has been operating since 1918. Specializing in aseptic manufacturing of Injectable Medicinal Products, IBI has established direct commercial presence in the UK, Germany, and Italy, while also exporting through alliances to more than 20 countries worldwide, including the US, Australia, and Europe. IBI offers comprehensive CDMO services, including advanced formulation, process development, and GMP manufacturing of sterile finished products. Their expertise extends to developing solutions and freeze-dried powders for both chemical and biotech active ingredients, such as small molecules, monoclonal antibodies, recombinant proteins, oligonucleotides, and nanoparticle technologies. IBI is certified by FDA, AIFA (EU), EDQM, TGA. More information: www.ibi-lorenzini.com Business Development: bd@ibi-lorenzini.com • GMP production for biological medicinal products (active substance from CHO cell culture, peptides, monoclonal antibodies) • GMP production of sterile drug products • GMP production of sterile API and finished products • CDMO and GMP production for orals, topicals, injectables • Aseptic filling of injectable medicinal products • Micro and nanoparticles formulations aimed to delivery of different classes of active molecules • Pharmaceutical development • Analytical validations, stability testing • MA and IMP registration and Batch Release services • Investigational Medicinal Product production